Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human gut fecal

ABSTRACT: Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome

PROVIDER: PRJNA391915 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR5799800_1.fastq.gz	Fastqsanger.gz
	SRR5799800_2.fastq.gz	Fastqsanger.gz
	SRR5799810_1.fastq.gz	Fastqsanger.gz
	SRR5799810_2.fastq.gz	Fastqsanger.gz
	SRR5799820_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 1350

Similar Datasets

Project description:Increased ileal IgA production and IgA-coated bacteria in diarrhoea-predominant irritable bowel syndrome

| PRJNA589202 | ENA

Colonic proteome signature in immunoproteasome-deficient stressed mice and its relevance for irritable bowel syndrome

Project description:A role for immunoproteasome in the regulation of intestinal permeability has been previously suggested both in mice during water avoidance stress (WAS) and in patients with irritable bowel syndrome (IBS). We thus aimed (i) to evaluate the colonic proteome in wild-type (wt) and β2i immunoproteasome subunit knock-out (β2i-/-) mice during WAS and (ii) to investigate the colonic expression of 49 ubiquitinated-proteins in diarrhea-predominant IBS patients (IBS-D).

2018-12-05 | PXD011199 | Pride

An Evaluation of Cultured Milk Drink on Immune Status of Patients With Irritable Bowel Syndrome: Constipation Predominant

Project description:Our previous work on the use of probiotics improved the clinical symptoms in irritable bowel syndrome with constipation-predominant. This study would like to explore further use of probiotics in the immune system of the patients with irritable bowel syndrome.

| 2359101 | ecrin-mdr-crc

Fecal microbiota

Project description:ASSESSMENT OF THE FECAL MICROBIOME IN HEALTHY VOLUNTEERS AND IRRITABLE BOWEL SYNDROME PATIENTS

| PRJNA524547 | ENA

Project description:Irritable bowel syndrome-related differences in the fecal microbiome after the rifaximin treatment

| PRJEB11252 | ENA

Fecal microbiota transplantation in irritable bowel syndrome patients

Project description:Fecal microbiota transplantation in irritable bowel syndrome patients

| PRJEB65418 | ENA

The microbiota metabolite, phloroglucinol, confers long-term protection against inflammation

Project description:Phloroglucinol is a key byproduct of gut microbial metabolism that has been widely used as 25 a treatment for irritable bowel syndrome. Here, we demonstrate that phloroglucinol tempers macrophage responses to pro-inflammatory pathogens and stimuli. In vivo, phloroglucinol administration decreases gut and extraintestinal inflammation in murine models of inflammatory bowel disease and systemic infection. The metabolite induces modest modifications in the microbiota. However, the presence of an active microbiota is required to preserve its anti-inflammatory activity. 30 Remarkably, the protective effect of phloroglucinol lasts partially at least 6 months. Single-cell transcriptomic analysis of bone marrow progenitors demonstrates the capacity of the metabolite to induce long-lasting innate immune training in hematopoietic lineages, at least partially through the participation of the receptor and transcription factor, aryl hydrocarbon receptor (AhR). Phloroglucinol induces alterations in metabolic and epigenetic pathways that are most prevalent 35 in upstream progenitors as hallmarks of central trained immunity. These data identify phloroglucinol as a dietary-derived compound capable of inducing central trained immunity and modulating the response of the host to inflammatory insults.

2024-12-09 | GSE246268 | GEO

Project description:Gut microbiota in mice with damp-heat diarrhea-predominant irritable bowel syndrome

| PRJNA1119274 | ENA

Gene expression analysis of rectal mucosa in chronic irritable bowel syndrome (IBS) compared to healthy volunteers (HV)

Project description:An investigation of gene expression changes in rectal biopsies from donors with IBS compared to controls to begin to understand this complex syndrome. To further investigate differences between IBS groups (constipation and diarrhoea predominant) (part1) and how IBS relates to bacterial infection (part2) with biopsies taken 6 months after Campylobacter jejuni infection. Part1: 18 Constipation predominant IBS subjects (IBS-C) and 27 diarrhoea predominant IBS subjects (IBS-D) compared to 21 healthy volunteers (HV). Part2: 21 Campylobacter jejuni infection (PIBD, PIBS, PINIBS) compared to 19 healthy volunteers (HV). PIBD = post Campylobacter infection with IBS (within 6 months) PIBS = post infection IBS (unknown time point and organism) PINIBS = post Campylobacter infection with no resulting IBS

2012-07-12 | E-GEOD-36701 | biostudies-arrayexpress

The fecal mycobiome in patients with Irritable Bowel Syndrome

Project description:The fecal mycobiome in patients with Irritable Bowel Syndrome

| PRJEB42375 | ENA